.png)
.png)
.png)
.png)
.png)
AEVOLVE is a powerful channel that brings fintech and revolutionary medical science together to accelerate the financing of medical innovations. It is a practical vehicle for bringing health-related innovations to their next stages of development, so patients can access and benefit from them faster.
The global pharmaceutical and biotechnology industry generate over a trillion dollars in annual sales making it one of the most powerful sectors in the world. Yet it is no secret that the reputation of “BIG PHARMA” has declined over the years. The public trust has been shaken with “BIG PHARMA” scandals that simply expose the same recurring problem: The disease of greed has infected the industry.
The victims of this disease, however, are everyday people. Us. The very people that rely on this industry for medical solutions to improve our health or find relief from suffering. But even with public awareness campaigns to rally against social injustices that have caused death, financial ruin or limit the progress or release of new medical technologies, we see that there has been no significant systemic change.
We in the crypto community are familiar with a similar scenario. Initially rejecting the crypto sector, today, major financial institutions and governments are changing their tune. It is not that blockchain aimed to change the original system, transformation is happening because another system was made possible.
What if there was a way to leverage the technological and financial channels of blockchain to directly finance medical innovations? What if it was possible to introduce a new way to empower scientists, researchers and medical innovators with financial strength and give their projects awareness to accelerate innovations so it goes from the lab and into the hands of the patients that desperately need them? And what if the opportunity to make this change and positively impact everyone involved is here right now?
The crypto-movement has created a rapid transfer of wealth over the last few years that continues to change lives. It’s time to use that power to save lives as well.
At AEVOLVE, we say, “BIG PHARMA IS SICK, WE ARE THE CURE.” Become the answer.
Aevolve aims to serve the majority of research applications (85%) that are submitted to governments globally go unfunded. This is a source of tremendous life-saving value, as well as new opportunities for growth and innovation.
The global biotechnology market alone is expected to reach USD 727.1 billion by 2025.
Project to launch initial treatment reservations and/or products as secured offerings on Biospheres estimated to be worth at least USD 1 billion.
The Aevolve Website serves for information purposes only and does not constitute research. This site and all materials, documents and information used therein or distributed in the context of its publication do not constitute or form part of and should not be construed as, an offer (public or private) or a solicitation of offers (public or private) to purchase or subscribe for or sell shares or other securities of the Company or any of its affiliates or subsidiaries in any jurisdiction or an inducement to enter into investment activity in any jurisdiction, and may not be used for such purposes.
This website may contain specific forward-looking statements, e.g. statements including terms like “believe”, “assume”, “expect”, “forecast”, “project”, “may”, “could”, “might”, “will” or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of Aevolve or any of its affiliates or subsidiaries and those explicitly or implicitly presumed in these statements.
These factors include, but are not limited to: (1) general market, macroeconomic, governmental and regulatory trends, (2) movements in securities markets, exchange rates and interest rates and (3) other risks and uncertainties inherent in our business. Against the background of these uncertainties, you should not rely on forwardlooking statements. Neither the Company nor any of its affiliates or subsidiaries or their respective bodies, executives, employees and advisers assume any responsibility to prepare or disseminate any supplement, amendment, update or revision to any of the information, opinions or forward-looking statements contained in this website or to adapt them to any change in events, conditions or circumstances, except as required by applicable law or regulation.
Any – including only partial – reproduction of any article or picture included in this website is solely permitted based on an authorization from Aevolve. No responsibility is assumed in case of unsolicited delivery.